Phase 1 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults of any ethnic background aged 18 or older (specific age ranges and gender requirements apply depending on which group a person is enrolled in — confirm with trial site)
- People aged 60 or older who have been diagnosed with mild cognitive impairment (for one specific group)
- People aged 60 or older who have been diagnosed with mild Alzheimer's disease (for one specific group)
- People aged 18 or older who have brain metastases confirmed by imaging and tissue testing, with the original cancer being a solid tumour (for Parts II and III)
- People whose brain tumour(s) are suitable for a targeted form of radiation treatment called stereotactic radiosurgery or radiotherapy (for Parts II and III)
- People taking the steroid medication dexamethasone, provided the dose has been stable around the time of key scans (for Parts II and III)
- People whose doctors estimate they have more than 6 months to live (for Parts II and III)
- All participants must be willing and able to give informed consent
Who may not be able to join:
- People who have previously had brain radiation treatment to the specific area of the brain being studied in this trial
- People in certain groups whose score on a standard memory and thinking test (called the MoCA) is below 26 (applies to specific groups — confirm with trial site)
- People who weigh more than 136 kg, due to scanner table limits
- People with pacemakers, cerebral aneurysm clips, shrapnel injuries, or implanted electronic devices that are not compatible with MRI
- People who are pregnant
- People with severe claustrophobia that would prevent lying inside an MRI scanner for 45 to 60 minutes
- People with a known allergic or adverse reaction to the MRI contrast dye called Gd-DTPA
- People who are unable to lie still for 45 to 60 minutes
- People with a high risk of a serious kidney-related condition called nephrogenic systemic fibrosis
- People who decline to go ahead with the procedure
- People who are not well enough to undergo MRI scanning
- People who are unable to complete the MRI for any reason
- For certain groups focused on memory and thinking: people with specific types of stroke-related brain changes or moderate to severe white matter disease on brain imaging
- For certain groups focused on memory and thinking: people with any other structural brain abnormality that could affect thinking or memory
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Charles Cunningham, PhD, Sunnybrook Research Institute
Phone: 416.480.6100
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Is an MRI image produced? Y/N?
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.